STOCK TITAN
  1. Home
  2. News
  3. AMRX

Amneal Pharmaceuticals Inc - AMRX STOCK NEWS

Welcome to our dedicated news page for Amneal Pharmaceuticals (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amneal Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amneal Pharmaceuticals's position in the market.

News
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) receives FDA approval for Over-the-Counter Naloxone Hydrochloride Nasal Spray, offering an affordable alternative to NARCAN®. The generic equivalent aims to combat opioid overdose emergencies, providing life-saving treatment without a prescription. Amneal's commitment to public health and accessibility drives the launch of this medication, important in the face of rising opioid-related fatalities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
fda approval
-
News
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. launches PEMRYDI RTU®, the first ready-to-use version of pemetrexed for injection, catering to non-squamous non-small cell lung cancer and malignant pleural mesothelioma patients. The product eliminates the need for reconstitution, dilution, or refrigeration, enhancing pharmacy efficiency. Amneal plans to introduce two to three branded oncology 505(b)(2) products annually, with PEMRYDI RTU® being the first in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
-
News
Amneal to Report First Quarter 2024 Results on May 3, 2024
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) will release its first quarter 2024 financial results on May 3, 2024, followed by a conference call and webcast. Investors can access the financial results and webcast through the Investor Relations section of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences earnings
News
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) celebrates its listing on the Nasdaq Stock Exchange. Co-founders and Co-CEOs, Chirag and Chintu Patel, will ring the closing bell on April 2, 2024. The company emphasizes its growth as a global pharmaceutical leader with a diverse portfolio of essential medicines, focusing on patient access, affordability, innovation, and quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
News
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) receives FDA approval for ciprofloxacin and dexamethasone otic suspension, a new high-value product for treating ear infections. The product is indicated for Acute Otitis Externa in pediatric, adult, and elderly patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
fda approval
-
News
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) reports Q4 2023 net revenue of $617 million, with a GAAP net loss of $99 million. Full-year 2023 net revenue reaches $2.39 billion. The company provides 2024 financial guidance of $2.55 to $2.65 billion in net revenue and $580 to $620 million in Adjusted EBITDA. The Co-CEOs highlight successful execution and growth, emphasizing the importance of providing high-quality, affordable medicines in a dynamic industry landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
earnings
News
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) has entered an exclusive licensing agreement with Zambon Biotech SA for IPX203, a novel oral formulation of carbidopa/levodopa extended-release capsules for Parkinson's disease in Europe. Zambon will handle regulatory approval and commercialization in Europe. This partnership aligns with Amneal's global strategy to provide access to their products worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
News
Amneal to Participate at Upcoming Investor Conference
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (AMRX) Co-CEO to participate in Barclays 26th Annual Global Healthcare Conference in Miami on March 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.27%
Tags
conferences
-
News
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
Rhea-AI Summary
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) has submitted a Complete Response resubmission to the FDA for IPX203, an oral formulation of carbidopa/levodopa extended-release capsules for Parkinson’s disease. The resubmission included data from a healthy volunteer study and no additional studies were requested. The company aims to launch the treatment in the second half of 2024, pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
News
Deb Autor, Former FDA Deputy Commissioner, Appointed CEO of Healthcare Innovation Catalysts
Rhea-AI Summary
Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined Healthcare Innovation Catalysts, Inc. (HIC) as its first Chief Executive Officer. With over 30 years of experience in government and regulated industries, Ms. Autor brings expertise in regulatory, quality, compliance, business strategy, policy, and law. Her appointment is expected to further HIC's role as a sought-after advisor to global life sciences organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
none
Stock AMRX logo
Amneal Pharmaceuticals Inc

Nasdaq:AMRX

AMRX Rankings

#1926 Ranked by Market Cap
#238 Ranked by Stock Gains
N/A Ranked by Dividends

AMRX Stock Data

1.68B
123.43M
59.78%
29.02%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bridgewater

About AMRX

an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.